title: Tinea capitis in California children: a population-based study of a growing epidemic.
abstract: OBJECTIVE
  To describe trends in tinea capitis incidence among California children and to determine subpopulations at increased risk.
  
  
  METHODS
  Retrospective population-based study.
  
  
  METHODS
  California, 1984 through 1993.
  
  
  METHODS
  Children < 10 years of age enrolled in Medi-Cal.
  
  
  METHODS
  California Medi-Cal provider data for first-time prescriptions of oral griseofulvin suspension were used to estimate annual incidence of tinea capitis and calculate risk ratios.
  
  
  RESULTS
  From 1984 through 1993, the incident rate for prescriptions of oral griseofulvin suspension increased by 84.2% for all children, 140.4% for white children, and 209.7% for African-American children. In 1993, incidence rates (per 10,000 enrolled) were 252.1 claimants for African-American children, 23.1 for white, 17.5 for Hispanic, and 14.3 for Asian/Pacific Islander. The highest rate by location was San Francisco County (172.2). In age groups < 5 years and 5 to 9 years, African-American children were 13.1 and 17.6 times more likely to be prescribed griseofulvin than Hispanic children. Since 1987, incidence rates for children 5 to 9 years of age were higher compared with children ages < 5 years.
  
  
  CONCLUSIONS
  Tinea capitis is epidemic among California children with higher rates in the northern counties studied. African-American children are the most affected by this epidemic; however, white children have also experienced increased rates.
authors.affiliation: Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
authors.forename: M N
authors.initials: MN
authors.lastname: Lobato
authors.forename: D J
authors.initials: DJ
authors.lastname: Vugia
authors.forename: I J
authors.initials: IJ
authors.lastname: Frieden
mesh_terms: D000284:Administration, Oral; D002140:California / Q000453:epidemiology; D002648:Child; D002675:Child, Preschool; D004196:Disease Outbreaks; D005260:Female; D006118:Griseofulvin / Q000627:therapeutic use*; D006801:Humans; D015994:Incidence; D007223:Infant; D008297:Male; D012189:Retrospective Studies; D013535:Suspensions; D014006:Tinea Capitis / Q000188:drug therapy / Q000453:epidemiology* / Q000208:ethnology
chemical_list: D013535:Suspensions; D006118:Griseofulvin